Clinical management for Candida auris infection: an integrative review
Article Sidebar
Main Article Content
Abstract
ABSTRACT
Clinical management for Candida auris infection: an integrative review
Introduction: Candida auris has been presented as a highly virulent fungus with important resistance capacity. It is considered an emerging, opportunistic fungus and an agent of infections with high mortality rates. Its mechanisms of resistance and morphological plasticity are tools that help this fungus in its dissemination. Colonizing especially the skin and hospital fomites for long periods of time, it makes immune debilitated patients its target. Objective: To provide information on clinical management in the treatment of C. auris infection, in addition to exposing the mechanisms of resistance against the main antifungals available, hospital control measures and the type of population most vulnerable to this fungal infection. Method: This is an integrative review with the synthesis of articles searched in the PubMed, BVS and SciELO databases in the period 2021-2023. Articles that aimed at therapeutic strategies and clinical management of patients infected with C. auris were selected. Results: Eight articles were selected to compose this review, after reading and excluding duplicates. The articles dealt with the design of experimental studies, cohort, case reports, in addition to other reviews. The database that most contributed to the research was PubMed. Conclusion: The use of echinocandin-derived antifungals proved to be the first line of treatment for cases of this fungal infection for all currently identified strains. In addition, measures of asepsis and hygiene of the infected patient in the hospital environment should be prioritized in confirmed cases.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright Statement - Policy Proposal for Open Access Journals
Authors who publish in the Brazilian Journal of Natural Sciences (BJNS) agree to the following terms: 1 - Authors retain the copyright and grant the journal the right to first publication, with the work simultaneously licensed under the Creative Commons Attribution License allowing sharing of the work with recognition of the authorship of the work and initial publication in this journal. 2 - Authors are authorized to assume additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (eg, publishing in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal. 3 - Authors are allowed and encouraged to publish and distribute their work online (eg in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes, as well as increase the impact and citation of published work. This is an open access article under the CC-BY license
(http://creativecommons.org/licenses/by/4.0)
References
REFERÊNCIAS
Chen J, Tian S, Han X, Chu Y, Wang Q, Zhou B, et al. Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris. BMC Infectious Diseases. 11 de novembro de 2020;20(1):827.
Rhodes J, Fisher MC. Global epidemiology of emerging Candida auris. Current Opinion in Microbiology. dezembro de 2019;52:84–9.
Černáková L, Roudbary M, Brás S, Tafaj S, Rodrigues CF. Candida auris: A Quick Review on Identification, Current Treatments, and Challenges. IJMS. 25 de abril de 2021;22(9):4470.
De Melo CC, De Sousa BR, Da Costa GL, Oliveira MME, De Lima-Neto RG. Colonized patients by Candida auris: Third and largest outbreak in Brazil and impact of biofilm formation. Front Cell Infect Microbiol. 23 de janeiro de 2023;13:1033707.
Sanyaolu A, Okorie C, Marinkovic A, Abbasi AF, Prakash S, Mangat J, et al. Candida auris : An Overview of the Emerging Drug-Resistant Fungal Infection. Infection & Chemotheraphy. 2022;54(2):236.
Bandara N, Samaranayake L. Emerging and future strategies in the management of recalcitrant Candida auris. Medical Mycology. 17 de março de 2022;60(4):myac008.
Ramos LDS, Silva LN, De Mello TP, Frota HF, Branquinha MH, Dos Santos ALS. Prospective Medicines against the Widespread, Emergent, and Multidrug resistant Opportunistic Fungal Pathogen Candida auris: A Breath of Hope. CTMC. junho de 2022;22(16):1297–305.
Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJS. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. Journal of Medical Microbiology. 1o de janeiro de 2013; 62(1):10–24.
Du H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. Xue C, organizador. PLoS Pathogens. 22 de outubro de 2020;16(10):e1008921.
Roig Martí C, Jiménez Sierra JJ, Pérez Catalán I, Gomila Sard B, Cardenal Álvarez A, Bellés Medall MD. Management of cutaneous and systemic involvement by Candida auris. Rev Esp Quimioter. 20 de janeiro de 2022;35(1):84–6.
Identification of Candida auris | Candida auris | Fungal Diseases | CDC [Internet]. [citado 25 de março de 2023]. Disponível em: https://www.cdc.gov/fungal/candida-auris/identification.html
Nota Técnica GVIMS/GGTES/ANVISA no 02/2022 - PRIMEIRA VERSÃO — Agência Nacional de Vigilância Sanitária - Anvisa [Internet]. [citado 25 de março de 2023]. Disponível em: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/servicosdesaude/notas-tecnicas/2022/nota-tecnica-gvims-ggtes-anvisa-no-02-2022/view
Pandya N, Cag Y, Pandak N, Pekok AU, Poojary A, Ayoade F, et al. International Multicentre Study of Candida auris Infections. Journal of Fungi (Basel, Switzerland). 19 de outubro de 2021;7(10):878.
Corcione S, Montrucchio G, Shbaklo N, De Benedetto I, Sales G, Cedrone M, et al. First Cases of Candida auris in a Referral Intensive Care Unit in Piedmont Region, Italy. Microorganisms. 27 de julho de 2022;10(8):1521.
Lewis SR, Schofield‐Robinson OJ, Rhodes S, Smith AF. Chlorhexidine bathing of the critically ill for the prevention of hospital‐acquired infection. Cochrane Database of Systematic Reviews [Internet]. 2019 [citado 20 de abril de 2023];(8). Disponível em: https://www.readcube.com/articles/10.1002%2F14651858.cd012248.pub2
Zerrouki H, Ibrahim A, Rebiahi SA, Elhabiri Y, Benhaddouche DE, de Groot T, et al. Emergence of Candida auris in intensive care units in Algeria. Mycoses. 2022;65(7):753–9.
Hilal-Dandan, R.; Brunton, L. Manual de Farmacologia e Terapêutica de Goodman & Gilman. Porto Alegre: Grupo A, 2015.
Whalen, Karen; Panavelil, T.A.; Finkel, R. Farmacologia ilustrada. 6 ed. Porto Alegre: Artmed, 2016, 670 p.
Treatment and Management of C. auris Infections and Colonization | Candida auris | Fungal Diseases | CDC [Internet]. [citado 19 de março de 2023]. Disponível em: https://www.cdc.gov/fungal/candida-auris/c-auris-treatment.html
Gómez-Gaviria M, Ramírez-Sotelo U, Mora-Montes HM. Non-albicans Candida Species: Immune Response, Evasion Mechanisms, and New Plant-Derived Alternative Therapies. Journal of Fungi (Basel, Switzerland). 21 de dezembro de 2022;9(1):11.
Tortorano AM, Prigitano A, Morroni G, Brescini L, Barchiesi F. Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches. Infection and Drug Resistance. dezembro de 2021;Volume 14:5543–53.
Sathyapalan DT, Antony R, Nampoothiri V, Kumar A, Shashindran N, James J, et al. Evaluating the measures taken to contain a Candida auris outbreak in a tertiary care hospital in South India: an outbreak investigational study. BMC Infectious Diseases. dezembro de 2021;21(1):425.
Zhou J, Li J, Cheong I, Liu NN, Wang H. Evaluation of artemisinin derivative artemether as a fluconazole potentiator through inhibition of Pdr5. Bioorganic & Medicinal Chemistry. agosto de 2021;44:116293.
Riera FO, Caeiro JP, Angiolini SC, Vigezzi C, Rodriguez E, Icely PA, et al. Invasive Candidiasis: Update and Current Challenges in the Management of This Mycosis in South America. Antibiotics (Basel, Switzerland). 30 de junho de 2022;11(7):877.
Paniágua AL, Correia AF, Pereira LC, De Alencar BM, Silva FBA, Almeida RM, et al. Inhibitory effects of Lactobacillus casei Shirota against both Candida auris and Candida spp. isolates that cause vulvovaginal candidiasis and are resistant to antifungals. BMC complementary medicine and therapies. dezembro de 2021;21(1):237.
Khan T, Suleman M, Ali SS, Sarwar MF, Ali I, Ali L, et al. Subtractive proteomics assisted therapeutic targets mining and designing ensemble vaccine against Candida auris for immune response induction. Computers in Biology and Medicine. junho de 2022;145:105462.
Khanina A, Tio SY, Ananda-Rajah MR, Kidd SE, Williams E, Chee L, et al. Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021. Internal Medicine Journal. 2021;51(S7):18–36.
Fathima K, Khan N, Faraz A, Kazmi SY, Motery AS al. Epidemiological analysis and successful management of a candida auris outbreak in a secondary care hospital setting in saudi arabia; an outbreak report. Journal of Ayub Medical College Abbottabad [Internet]. 24 de junho de 2022 [citado 20 de abril de 2023];34(3 (SUPPL 1)). Disponível em: https://jamc.Ayubmed.Edu.Pk/jamc/index.Php/jamc/article/view/9274
Li J, Coste AT, Bachmann D, Sanglard D, Lamoth F. Assessment of the In Vitro and In Vivo Antifungal Activity of NSC319726 against Candida auris. O’Meara TR, organizador. Microbiology Spectrum. 22 de dezembro de 2021;9(3):e01395-21.
Najeeb H, Siddiqui SA, Anas Z, Ali SH, Usmani SUR, Jawed F, et al. The Menace of Candida auris Epidemic Amidst the COVID-19 Pandemic: A Systematic Review. Diseases. 29 de agosto de 2022;10(3):58.
Sharma D, Paul RA, Rudramurthy SM, Kashyap N, Bhattacharya S, Soman R, et al. Impact of FKS1 Genotype on Echinocandin In Vitro Susceptibility in Candida auris and In Vivo Response in a Murine Model of Infection. Antimicrobial Agents and Chemotherapy. 18 de janeiro de 2022;66(1):e01652-21.
Chan W, Chow FWN, Tsang CC, Liu X, Yao W, Chan TTY, et al. Induction of amphotericin B resistance in susceptible Candida auris by extracellular vesicles. Emerging Microbes & Infections. 31 de dezembro de 2022;11(1):1900–9.
Demers EG, Stajich JE, Ashare A, Occhipinti P, Hogan DA. Balancing Positive and Negative Selection: In Vivo Evolution of Candida lusitaniae MRR1. mBio. 2021;12(2).
Abduljalil H, Bakri A, Albashaireh K, Alshanta OA, Brown JL, Sherry L, et al. Screening the TocriscreenTM bioactive compound library in search for inhibitors of Candida biofilm formation. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. setembro de 2022;130(9):568–77.
Ferrando G, Castagnola E. Prophylaxis of Invasive Fungal Infection in Neonates: A Narrative Review for Practical Purposes. Journal of Fungi (Basel, Switzerland). 26 de janeiro de 2023;9(2):164.
Flodgren G, Conterno LO, Mayhew A, Omar O, Pereira CR, Shepperd S. Interventions to improve professional adherence to guidelines for prevention of device‐related infections. Cochrane Database of Systematic Reviews [Internet]. 2013 [citado 18 de março de 2023];(3). Disponível em: https://www.readcube.com/articles/10.1002%2F14651858.cd006559.pub2
Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 15 de janeiro de 2017;64(2):134–40.
Revie NM, Iyer KR, Robbins N, Cowen LE. Antifungal Drug Resistance: Evolution, Mechanisms and Impact. Current Opinion in Microbiology. outubro de 2018;45:70–6.